Skip to main content
×
×
Home

NICE guidance in schizophrenia: how generalisable are drug trials?

  • Tom Burns (a1)
Abstract
Aims and Method

To test the National Institute for Clinical Excellence (NICE) assertion that characteristics of participants in the majority of clinical drug trials in schizophrenia do not reflect clinical practice. In particular they were concerned about the relative exclusion of women, older adults and patients with comorbidity. The baseline characteristics of a sample of 600 patients with schizophrenia recruited to be as representative as possible of UK community practice were compared with those from one of the largest international drug trials of an atypical antipsychotic.

Results

Although comparisons could only be made on a limited range of characteristics the two samples were broadly comparable.

Clinical Implications

Current drug trials from pharmaceutical companies may have more relevance to clinical practice than their stated exclusion criteria may indicate.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      NICE guidance in schizophrenia: how generalisable are drug trials?
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      NICE guidance in schizophrenia: how generalisable are drug trials?
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      NICE guidance in schizophrenia: how generalisable are drug trials?
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Hide All
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). Washington, DC: APA.
Csernansky, J. G., Mahmoud, R. & Brenner, R. (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine, 346, 1622.
Geddes, J. (2002) Prevention of relapses in schizophrenia. New England Journal of Medicine, 346, 5658.
Harrison-Read, P., Lucas, B., Tyrer, P., et al (2002) Heavy users of acute psychiatric beds: randomized controlled trial of enhanced community management in an outer London borough. Psychological Medicine, 32, 403416.
Montgomery, S. A. & ÅSberg, M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382389.
National Institute for Clinical Excellence (2002) Technology Appraisal Guidance No. 43. Guidance on the use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. London: NICE.
Thornley, B. & Adams, C. (1998) Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ, 317, 11811184.
Tollefson, G. D., Beasley, C. M., Tran, P.V., et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154, 457465.
Tollefson, G.D., Sanger, T. M., Lu, Y., et al (1998) Depressive signs and symptoms in schizophrenia. Archives of General Psychiatry, 55, 250258.
Von Knorring, L. & Lindstrom, E. (1995) Principal components and further possibilities with the PANSS. Acta Psychiatrica Scandinavica Supplementum, 388, 510.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 0955-6036
  • EISSN: 1472-1473
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 2 *
Loading metrics...

Abstract views

Total abstract views: 57 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 22nd July 2018. This data will be updated every 24 hours.

NICE guidance in schizophrenia: how generalisable are drug trials?

  • Tom Burns (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *